DexCom/$DXCM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About DexCom
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Ticker
$DXCM
Sector
Primary listing
Employees
10,250
Headquarters
Website
DexCom Metrics
BasicAdvanced
$26B
46.63
$1.43
1.49
-
Price and volume
Market cap
$26B
Beta
1.49
52-week high
$93.25
52-week low
$57.52
Average daily volume
5.8M
Financial strength
Current ratio
1.52
Quick ratio
1.302
Long term debt to equity
50.274
Total debt to equity
98.057
Interest coverage (TTM)
24.20%
Profitability
EBITDA (TTM)
923.3
Gross margin (TTM)
58.77%
Net profit margin (TTM)
13.29%
Operating margin (TTM)
15.98%
Effective tax rate (TTM)
27.11%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
6.08%
Return on equity (TTM)
22.83%
Valuation
Price to earnings (TTM)
46.626
Price to revenue (TTM)
6.07
Price to book
10.15
Price to tangible book (TTM)
10.61
Price to free cash flow (TTM)
45.738
Free cash flow yield (TTM)
2.19%
Free cash flow per share (TTM)
1.456
Growth
Revenue change (TTM)
9.30%
Earnings per share change (TTM)
-11.42%
3-year revenue growth (CAGR)
17.17%
10-year revenue growth (CAGR)
29.70%
3-year earnings per share growth (CAGR)
36.59%
10-year earnings per share growth (CAGR)
35.98%
What the Analysts think about DexCom
Analyst ratings (Buy, Hold, Sell) for DexCom stock.
Bulls say / Bears say
Dexcom’s G7 15 Day CGM system received FDA clearance on April 10, 2025, offering 15.5 days of wear and 8.0% MARD accuracy, boosting shares 2.9% and reinforcing its technological leadership (Barron's).
According to J.P. Morgan, while the CMS competitive bidding proposal may create near-term pricing pressure, it is unlikely to fundamentally alter Dexcom’s long-term growth trajectory given its leading market position (Reuters).
Despite the FDA warning letter, Dexcom stated it does not expect any material impact on its manufacturing capacity or 2025 sales guidance, highlighting operational resilience and strong cash position (Reuters).
CMS’s proposed competitive bidding program for CGMs and insulin pumps could subject roughly 15% of Dexcom’s U.S. CGM users to mid-teens pricing cuts, leading to a 3.5% stock drop on July 1, 2025 (Reuters).
Dexcom received a warning letter from the FDA on March 7, 2025, citing deficiencies in manufacturing processes and quality systems at its San Diego and Mesa facilities, driving a nearly 7% share decline and underscoring regulatory risks (Reuters).
Abbott’s continuous glucose monitoring sales surged 21.4% year-over-year to $1.9 billion in Q2 2025, intensifying competitive pressure on Dexcom’s market share and potentially eroding future growth prospects (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
DexCom Financial Performance
Revenues and expenses
DexCom Earnings Performance
Company profitability
DexCom News
AllArticlesVideos
Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time.
Business Wire3 weeks ago
Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA
Benzinga1 month ago
Dexcom Spotlights Upcoming Feature Launches, Improved Health Outcomes and Cost-Effectiveness With Dexcom Glucose Biosensing at EASD 2025
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DexCom stock?
DexCom (DXCM) has a market cap of $26B as of October 20, 2025.
What is the P/E ratio for DexCom stock?
The price to earnings (P/E) ratio for DexCom (DXCM) stock is 46.63 as of October 20, 2025.
Does DexCom stock pay dividends?
No, DexCom (DXCM) stock does not pay dividends to its shareholders as of October 20, 2025.
When is the next DexCom dividend payment date?
DexCom (DXCM) stock does not pay dividends to its shareholders.
What is the beta indicator for DexCom?
DexCom (DXCM) has a beta rating of 1.49. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.